top of page

Bayer secures FDA approval for Kovaltry haemophilia A drug

Bayer has secured approval from the US Food and Drug Administration (FDA) for Kovaltry to treat children and adults with haemophilia A. Kovaltry is an unmodified full-length recombinant factor VIII product, which is designed to reduce bleeding in patients with hemophilia A when administered prophylactically two or three times a week.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page